ZURA, KYG989201089

Zura Bio stock enters a key trial data phase

Published on 09/30/2026 at 05:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zura Bio stock has two Phase 2 readouts ahead after 247 and 91 patients completed enrollment. Second-quarter cash reached USD 205.1 million on June 30, 2026.

ZURA, KYG989201089, Illustration mit AI erstellt.

Zura Bio Limited (ISIN KYG989201089) is moving toward two pivotal Phase 2 readouts after completing enrollment in its lead tibulizumab studies. The company reported the second-quarter milestones on August 11, 2026, while its latest dated Frankfurt quote was EUR 3.64 on September 25, 2026.

Two Phase 2 readouts approach

According to CEO.CA on August 11, 2026, the TibuSHIELD study in hidradenitis suppurativa completed enrollment with 247 participants, while TibuSURE in systemic sclerosis reached 91 participants. The company expects topline TibuSHIELD data in the fourth quarter of 2026 and TibuSURE data in the first half of 2027.

The same release said Zura selected polymyalgia rheumatica as a third indication for tibulizumab and plans to begin the NEXUS-PMR Phase 2 study by the end of 2026. The timing makes clinical data the central valuation checkpoint, because tibulizumab remains investigational and has not received regulatory approval.

Losses rise with trial spending

Yahoo Finance reported on September 11, 2026, that second-quarter research and development expense reached USD 20.7 million, compared with USD 8.7 million in the year-earlier quarter. Net loss widened to USD 26.3 million, or USD 0.21 per share, from USD 16.0 million, or USD 0.17 per share.

Cash and cash equivalents stood at USD 205.1 million on June 30, 2026, and the company said that balance supports planned operations through the end of 2028. For investors, the contrast is clear: enrollment execution has advanced, but the cost of producing clinical evidence is also accelerating.

Analyst target stays above market

According to MarketBeat on September 11, 2026, seven analysts held a Moderate Buy consensus and an average 12-month price target of USD 17.00. The cited target compares with a Nasdaq price of USD 4.00 on September 29, 2026 at 4:00 p.m. ET, placing the market value at USD 380.0 million and the 52-week range at USD 3.13 to USD 7.44.

Frankfurt quote stays dated

Zura Bio was last at EUR 3.64 on Frankfurt on September 25, 2026. The company therefore enters its next phase with two defined data windows, USD 205.1 million in cash and a quarterly loss that reflects the expanding trial program.